President Ferdinand R. Marcos Jr. has appointed lawyer Melvin Matibag as the new director of the National Bureau of Investigation (NBI), a Malacañang official said Thursday. Presidential ...

NATIONAL Bureau of Investigation (NBI) chief Melvin Matibag on Monday vowed to uphold transparency, strengthen accountability, and maintain the bureau’s integrity in his first public remarks following ...

MANILA, Philippines — Executive Secretary Ralph Recto has called on National Bureau of Investigation (NBI) Director Melvin Matibag to strengthen the agency’s role in fighting crime and securing ...

Make this your preferred source to get more updates from this publisher on Google. Armed with a warrant of arrest, agents from the National Bureau of Investigation (NBI) Organized and Transnational ...

MANILA, Philippines — The National Bureau of Investigation (NBI) said on Wednesday that it dismantled the technical operations of a scamming hub within an exclusive village in Muntinlupa City recently ...

The National Bureau of Investigation (NBI) said Wednesday it is examining the statement of vlogger Jason Argota, who allegedly circulated fake and unauthorized medical records of President Ferdinand ...

MANILA, Philippines — President Ferdinand Marcos Jr. directed lawyer Melvin Matibag to make the National Bureau of Investigation (NBI) "a stronger instrument of stopping crime, attaining justice, ...

MANILA, Philippines — The National Bureau of Investigation (NBI) apprehended an individual for allegedly defrauding a Hong Kong-based company of around P50.6 million ($874,200) in gold investments.

MANILA, Philippines — President Ferdinand Marcos Jr. appointed lawyer Melvin Matibag—a former Cabinet Secretary to former chief executive Rodrigo Duterte—as the new director of the National Bureau of ...

DESPITE saying that President Marcos’s attention is not focused in the 2028 elections in the wake of Vice President Sara Duterte’s recent announcement of her presidential bid, two actions by the ...

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff came ...